Stockwatch

Date	Sym	Type	Headline
2025-04-16 16:05	UU:VKTX	News Release200	Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025
2025-03-26 07:05	UU:VKTX	News Release200	Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
2025-03-11 07:03	UU:VKTX	News Release200	Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
2025-03-04 16:05	UU:VKTX	News Release200	Viking Therapeutics to Participate at Upcoming Investor Conferences
2025-02-05 16:05	UU:VKTX	News Release200	Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
2025-01-29 16:05	UU:VKTX	News Release200	Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025
2025-01-08 07:03	UU:VKTX	News Release200	Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
2025-01-06 16:05	UU:VKTX	News Release200	Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
2024-11-19 16:03	UU:VKTX	News Release200	Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting(TM) 2024
2024-11-12 16:05	UU:VKTX	News Release200	Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting(TM) 2024
2024-11-04 06:30	UU:VKTX	News Release200	Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek(TM) 2024
2024-10-31 16:05	UU:VKTX	News Release200	Viking Therapeutics to Participate at Upcoming Investor Conferences
2024-10-28 16:05	UU:VKTX	News Release200	Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek(TM) 2024
2024-10-23 16:05	UU:VKTX	News Release200	Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
2024-10-16 16:05	UU:VKTX	News Release200	Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024
2024-10-09 07:00	UU:VKTX	News Release200	Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
2024-08-28 16:03	UU:VKTX	News Release200	Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference
2024-07-24 16:05	UU:VKTX	News Release200	Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
2024-07-17 16:05	UU:VKTX	News Release200	Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024
2024-06-24 07:33	UU:VKTX	News Release200	Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association
2024-06-04 07:05	UU:VKTX	News Release200	Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
2024-05-30 16:03	UU:VKTX	News Release200	Viking Therapeutics to Participate at Upcoming Investor Conferences
2024-04-24 16:05	UU:VKTX	News Release200	Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-04-22 06:00	UU:VKTX	News Release200	6 Stocks Positioned to Soar as Investors Focus on MASH